Journal of Clinical Pediatrics >
Research advances of the diagnosis and management for mucormycosis following hematopoietic stem cell transplant in children
Received date: 2022-01-05
Online published: 2023-04-07
The pediatric mucormycosis is a rare but often highly lethal complication after hematopoietic stem cell transplantation (HSCT). Of the hazard factors, immunosuppression post HSCT, neutropenia, graft-versus-host disease (GVHD), Iron overload, parenteral hyperalimentation, and the use of corticosteroid or calcineurin inhibitors, particularly in children, have been reported to be the commonest contributions to mucormycosis. An early diagnosis and combined treatment of mucormycosis is challenging due to the nature of often rapidly invasion and destruction. This article reviews the research advances in epidemiological characteristics, pathogenesis, diagnosis and treatment of mucormycosis in children after HSCT, and provides suggestions for further improvement of the diagnosis and treatment of mucormycosis in children after transplantation.
Key words： mucormycosis; hematopoietic stem cell transplant; diagnosis; management; child
Bixin Reviewer: XI , Qun HU , Xin ZHAO , Aiguo Reviser: LIU . Research advances of the diagnosis and management for mucormycosis following hematopoietic stem cell transplant in children[J]. Journal of Clinical Pediatrics, 2023 , 41(4) : 311 -315 . DOI: 10.12372/jcp.2023.22e0025
| [1] | Hassan MIA, Voigt K. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors[J]. Med Mycol, 2019, 57(Suppl 2): S245-S256. |
| [2] | Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis, 2019, 19(12): e405-e421. |
| [3] | Francis JR, Villanueva P, Bryant P, et al. Mucormycosis in children: review and recommendations for management[J]. J Pediatr Infect Dis Soc, 2018, 7(2): 159-164. |
| [4] | Gebremariam T, Liu M, Luo G, et al. CotH3 mediates fungal invasion of host cells during mucormycosis[J]. J Clin Invest, 2014, 124(1): 237-250. |
| [5] | Pana ZD, Seidel D, Skiada A, et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries[J]. BMC Infect Dis, 2016, 16(1): 667. |
| [6] | Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis[J]. Med Mycol, 2018, 56(Suppl 1): 93-101. |
| [7] | Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports[J]. Clin Microbiol Infect, 2019, 25(1): 26-34. |
| [8] | Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients[J]. Haematologica, 2017, 102(3): 433-444. |
| [9] | Jeong W, Keighley C, Wolfe R, et al. Contemporary management and clinical outcomes of mucormycosis: a systematic review and meta-analysis of case reports[J]. Int J Antimicrob Agents, 2019, 53(5): 589-597. |
| [10] | 梁官钊, 刘维达. 2019年欧洲毛霉病诊疗指南解读[J]. 中国真菌学杂志, 2021, 16(2): 116-120. |
| [11] | Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis[J]. J Antimicrob Chemother, 2015, 70(11): 3116-3123. |
| [12] | Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis, 2016, 16(7): 828-837. |
| [13] | Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis[J]. Clin Microbiol Infect, 2016, 22(9): 811. |
| [14] | Marty FM, Cornely OA, Mullane KM, et al. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species[J]. Mycoses, 2018, 61(7): 485-497. |
| [15] | Bhatnagar S, Mukherjee D, Salem AH, et al. Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach[J]. Cancer Chemother Pharmacol, 2021, 87(4): 465-474. |
/
| 〈 |
|
〉 |
